2. Search Result
Search Result
Results for "

π–π stacking interaction

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

2

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-151108
    IDO1/TDO-IN-4
    1 Publications Verification

    		 Indoleamine 2,3-Dioxygenase (IDO) Neurological Disease Inflammation/Immunology
    IDO1/TDO-IN-4 is a potent IDO1/TDO dual inhibitor, with IC50 values of 3.53 μM (IDO1) and 1.15 μM (TDO). IDO1/TDO-IN-4 forms hydrogen bond with IDO1, and π−π stacking interaction with TDO. IDO1/TDO-IN-4 can be used in the research of depression, and depression-induced infectious, metabolic, and autoimmune disorders .
    IDO1/TDO-IN-4
  • HY-113404
    DL-Dopa

    		Tyrosinase Dopamine Receptor Neurological Disease
    DL-Dopa is a dopamine precursor. It serves as a substrate for Mushroom Tyrosinase, which oxidizes it to dopaquinone, an intermediate in the DOPA-melanin polymerization process, and this reaction can be detected at 475 nm. DL-Dopa also forms synergistic hydrophobic and π-π stacking interactions with cationic surfactants. Its binding to cetylpyridinium chloride (HY-B1464) is stronger and exhibits better thermodynamic stability than its binding to benzalkonium chloride (HY-B2232). DL-Dopa can compensate for dopamine depletion in the brain and is applicable to research related to Parkinson's disease .
    DL-Dopa
  • HY-161308
    HPPD-IN-3

    		HPPD Others
    HPPD-IN-3 (compound 25) is a potent inhibitor of 4-Hydroxyphenylpyruvate dioxygenase (HPPD), with IC50 of 10 nM, more potency than Mesotrione (HY-12853) .
    HPPD-IN-3
  • HY-33821
    LXRβ ligand 1

    		LXR Others
    LXRβ ligand 1 is a LXR β ligand-binding domain agonist, with an EC50 of 57 μM and a Ki of 28 μM against human LXR β. LXRβ ligand 1 forms hydrogen bonds with His435, stabilizes the His-Trp activation switch, and locks the ligand-binding domain in an agonist conformation; its tert-butyl moiety occupies a hydrophobic subpocket, while its phenyl moiety forms a π-π stacking interaction with Phe329. LXRβ ligand 1 serves as a structural unit for the development of LXRβ modulators .
    LXRβ ligand 1
  • HY-151405
    Z164597606

    		Cholinesterase (ChE) Neurological Disease
    Z164597606 is a selective BChE inhibitor (IC50: 1.3 and 1.7 μM for eqBChE and hBChE). Z164597606 forms a π-π stacking interaction with the amino acid Trp82 of hBChE. Z164597606 can be used for the research of Alzheimer’s disease (AD) .
    Z164597606
  • HY-181171
    HIT-2

    		Estrogen Receptor/ERR Cancer
    HIT-2 is an estrogen receptor alpha (ERα) inhibitor that can bind to the ERα ligand binding domain. HIT-2 forms stable interactions including hydrogen bonds, π-π stacking, and hydrophobic contacts to disrupt ERα-driven signaling. HIT-2 exhibits antineoplastic activity against breast cancer. HIT-2 can be used for the research of breast cancer .
    HIT-2
  • HY-103084
    PDE5-IN-1

    		Phosphodiesterase (PDE) Cardiovascular Disease
    PDE5-IN-1 is an orally active, selective PDE5 inhibitor with an IC50 of 5.6 nM. PDE5-IN-1 forms hydrogen bond interactions with the Q817 residue in the catalytic domain of PDE5, and aromatic π-π stacking interactions with the F820 residue. PDE5-IN-1 exerts anti-cardiac hypertrophy and vasodilatory effects, reduces mean pulmonary arterial pressure and right ventricular hypertrophy index. PDE5-IN-1 can be used in the research of pulmonary arterial hypertension .
    PDE5-IN-1
  • HY-182783
    JNJ-10450232

    NTM-006

    		 Adenosine Receptor Neurological Disease Inflammation/Immunology
    NTM-006 is a selective and brain-penetrant adenosine A3 receptor (A3AR) agonist. NTM-006 selectively interacts with adenosine A3AR via π-π stacking with Phe168 and π-alkyl interactions receptor residues. NTM-006 inhibits Acetic acid (HY-Y0319)-induced writhing responses in mice. NTM-006 can be used for the research of chronic neuropathic pain, cancer-related pain, osteoarthritis-associated pain .
    JNJ-10450232
  • HY-N19818
    Glycybridin C

    		Phosphatase NF-κB Pregnane X Receptor (PXR) Cancer
    Glycybridin C is a Protein tyrosine phosphatase 1B (PTP1B) inhibitor and pregnane X receptor (PXR) ligand. Glycybridin C inhibits insulin and leptin signaling pathway negative regulation, LPS (HY-D1056)-induced NF-κB transcriptional activity. Glycybridin C forms hydrophobic and π-π stacking interactions with Met243, Phe288, Tyr306, and His407 residues of PXR. Glycybridin C can be used for the research of hepatocellular carcinoma, colorectal adenocarcinoma, breast carcinoma .
    Glycybridin C
  • HY-182030
    RSV fusion protein IN-1

    		RSV Infection
    RSV fusion protein IN-1 is an orally active RSV pre-fusion F protein inhibitor with an IC50 of 0.10 nM against RSV. RSV fusion protein IN-1 forms stable hydrogen bonds and π-π stacking interactions with pre-fusion F protein to block viral fusion and entry. RSV fusion protein IN-1 suppresses RSV F protein expression in epithelial cells. RSV fusion protein IN-1 reduces viral burden in the lungs of RSV-infected murine models.RSV fusion protein IN-1 can be used for the research of respiratory syncytial virus (RSV) infection .
    RSV fusion protein IN-1
  • HY-183105
    DC551040

    		Histone Demethylase Apoptosis Cancer
    DC551040 is an orally active and selective lysine demethylase 1 (LSD1) inhibitor with a human IC50 of 2.14 nM. DC551040 binds to LSD1 via π-π stacking with Trp552, polar interactions with Phe538, and covalent adduct formation with FAD, and disrupts the LSD1-GFI1B-CoREST complex. DC551040 induces H3K4me2 accumulation, apoptosis, and cell differentiation, activates STAT5, NF-κB, AKT, and IL6-STAT3 pathways, and upregulates IL6 expression. DC551040 can be used for the research of acute myeloid leukemia .
    DC551040
  • HY-182047
    PD-1/PD-L1-IN-61

    		PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-61 is a PD-1/PD-L1 interaction inhibitor with a human IC50 of 5.3 nM. PD-1/PD-L1-IN-61 embeds into the hydrophobic pocket at the PD-L1 dimer interface, stabilizing binding through hydrogen bonds and π-π stacking with PD-L1 residues. PD-1/PD-L1-IN-61 acts as an immune activator, enhances immune-killing activity of peripheral blood mononuclear cells against cancer cells, restores T-cell immune function, and promotes IFN-γ secretion. PD-1/PD-L1-IN-61 can be used for the research of triple-negative breast cancer .
    PD-1/PD-L1-IN-61

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: